CoChat

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Open access
Sabbaghi, MohammadA, Gil-Gómez, Gabriel, Guardia, Cristina, Servitja, Sonia, Arpí, Oriol, García-Alonso, Sara, Menendez, Silvia, Arumi-Uria, Montserrat, Serrano, Laia, Salido, Marta, Muntasell, Aura, Martínez-García, Maria, Zazo, Sandra, Chamizo, Cristina, González-Alonso, Paula, Madoz-Gúrpide, Juan, Eroles, Pilar, Arribas, Joaquin, Tusquets, Ignasi, Lluch, Ana, Pandiella, Atanasio, Rojo, Federico, Rovira, Ana, Albanell, Joan · 2017 · Clinical Cancer Research
Cited by 102

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance. Experimental Design: HER2-positive breast cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated in a pulse-fashion with T-DM1 to induce a resistant phenotype. Cellular and molecular effects of T-DM1 in parental versus resistant cells were compared. CDK1 kinase activity and cyclin B1 expression were assayed under various conditions. Genetic modifications to up- or downregulate cyclin B1 were conducted. Effects of T-DM1 on cyclin B1 levels, proliferation, and apoptosis were assayed in human HER2-positive breast cancer explants. Results: We obtained three cell lines with different levels of acquired T-DM1 resistance (HCC1954/TDR, HCC1419/TDR, and SKBR3/TDR cells). HER2 remained amplified in the resistant cells. Binding to HER2 and intracellular uptake of T-DM1 were maintained in resistant cells. T-DM1 induced cyclin B1 accumulation in sensitive but not resistant cells. Cyclin B1 knockdown by siRNA in parental cells induced T-DM1 resistance, while increased levels of cyclin B1 by silencing cdc20 partially sensitized resistant cells. In a series of 18 HER2-positive breast cancer fresh explants, T-DM1 effects on proliferation and apoptosis paralleled cyclin B1 accumulation. Conclusions: Defective cyclin B1 induction by T-DM1 mediates acquired resistance in HER2-positive breast cancer cells. These results support the testing of cyclin B1 induction upon T-DM1 treatment as a pharmacodynamic predictor in HER2-positive breast cancer. Clin Cancer Res; 23(22); 7006–19. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0696

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 102

Metadata

Authors
Sabbaghi, M., Gil-Gómez, G., Guardia, C., Servitja, S., Arpí, O., García-Alonso, S., Menendez, S., Arumi-Uria, M., Serrano, L., Salido, M., Muntasell, A., Martínez-García, M., Zazo, S., Chamizo, C., González-Alonso, P., Madoz-Gúrpide, J., Eroles, P., Arribas, J., Tusquets, I., Lluch, A., Pandiella, A., Rojo, F., Rovira, A., & Albanell, J.
Venue
Clinical Cancer Research
Published
2017-11-14
Volume
23
Issue
22
Pages
7006-7019
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2749536232
Cited by
102
References
7
FWCI
3.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0696
The paper
Sabbaghi, M., Gil-Gómez, G., Guardia, C., Servitja, S., Arpí, O., García-Alonso, S., Menendez, S., Arumi-Uria, M., Serrano, L., Salido, M., Muntasell, A., Martínez-García, M., Zazo, S., Chamizo, C., González-Alonso, P., Madoz-Gúrpide, J., Eroles, P., Arribas, J., Tusquets, I., . . . Albanell, J. (2017). Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.